机构

• 上海药物研究所 [5]

采集方式

• OAI收割 [5]

内容类型

• 期刊论文 [5]

发表日期

• 2023 [1]
• 2022 [3]
• 2021 [1]

学科主题

筛选

浏览/检索结果: 共5条，第1-5条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序题名升序题名降序作者升序作者降序发表日期升序发表日期降序 A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 卷号: 8, 期号: 1, 页码: 10 作者:  Zhang, Yumin;  Sun, Yuan;  Xie, Yuanchao;  Shang, Weijuan;  Wang, Zhen   |  收藏  |  浏览/下载：8/0  |  提交时间：2023/12/08 Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 卷号: 7, 期号: 1, 页码: 3 作者:  Zhang, Ruxue;  Zhang, Yumin;  Zheng, Wei;  Shang, Weijuan;  Wu, Yan   |  收藏  |  浏览/下载：24/0  |  提交时间：2022/06/15 Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2022, 页码: 9 作者:  Qian, Hong-jie;  Wang, Yu;  Zhang, Meng-qi;  Xie, Yuan-chao;  Wu, Qing-qing   |  收藏  |  浏览/下载：38/0  |  提交时间：2022/06/15 VV116  nucleoside analog  SARS-CoV-2  safety  pharmacokinetics  healthy subjects   Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2022, 页码: 13 作者:  Wu, Can-rong;  Yin, Wan-chao;  Jiang, Yi;  Xu, H. Eric   |  收藏  |  浏览/下载：16/0  |  提交时间：2022/06/15 COVID-19  SARS-CoV-2  structural biology  omicron  drug design  vaccine development   Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2 期刊论文  OAI收割 CELL RESEARCH, 2021, 页码: 3 作者:  Xie, Yuanchao;  Yin, Wanchao;  Zhang, Yumin;  Shang, Weijuan;  Wang, Zhen   |  收藏  |  浏览/下载：73/0  |  提交时间：2021/11/04